Evolocumab: Randomized Trial Results on Cognitive Function Published

By Hipa.ai Research · January 1, 2017

Synced daily from openFDA and ClinicalTrials.gov. Last sync: June 12, 2026.

Results from a randomized trial investigating the influence of evolocumab on cognitive function were published on 2017-01-01. The study, known as EBBINGHAUS, evaluated cognitive health in high cardiovascular risk subjects treated with the drug, making its findings available to the medical community.

Background

Evolocumab, also known by its brand name Repatha, is a medication primarily used to lower cholesterol levels. This particular study, EBBINGHAUS, focused on a specific aspect of its safety profile by assessing its potential impact on cognitive health. The trial was conducted in individuals with high cardiovascular risk, a population often requiring long-term lipid-lowering therapies, making the evaluation of cognitive effects particularly relevant for patient care and long-term treatment considerations.

Trial design

The EBBINGHAUS (Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects) study was a randomized trial specifically designed to investigate the effects of evolocumab on various measures of cognitive function. The trial aimed to provide comprehensive data on cognitive outcomes in subjects identified as having high cardiovascular risk, who were receiving treatment with evolocumab. This design allowed for a controlled assessment of any potential cognitive changes associated with the drug.

What this means

The publication of the EBBINGHAUS trial results provides clinicians, researchers, and patient advocates with critical access to data regarding evolocumab's influence on cognitive health. This information is essential for a comprehensive understanding of the drug's overall safety profile, particularly for its long-term use in high cardiovascular risk subjects. The availability of these findings allows for informed discussions about treatment benefits and potential considerations related to cognitive function when prescribing evolocumab.

Source

The information about the publication of these trial results was sourced from PubMed, a leading database of biomedical literature. The article, titled 'Cognitive Function in a Randomized Trial of Evolocumab', was published on 2017-01-01 in the New England Journal of Medicine, and is accessible via pubmed.ncbi.nlm.nih.gov (PubMed ID: 28813214).